<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933968</url>
  </required_header>
  <id_info>
    <org_study_id>P-106-001</org_study_id>
    <nct_id>NCT04933968</nct_id>
  </id_info>
  <brief_title>Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant</brief_title>
  <official_title>Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloVir</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlloVir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy&#xD;
      that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV),&#xD;
      influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following&#xD;
      hematopoietic cell transplant (HCT)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesis is that the administration of ALVR106, plus standard of care, to post&#xD;
      HCT patients suffering from infection with any of the four targeted viruses (RSV, influenza,&#xD;
      hMPV, and/or PIV) will be safe and demonstrate shorter time to resolution of the viral&#xD;
      infection (as measured by resolution of symptoms and viral load clearance in nasal swab)&#xD;
      compared to patients treated with placebo.&#xD;
&#xD;
      This trial will consist of two parts:&#xD;
&#xD;
      Part A - Dose Escalation in Patients with Upper Respiratory Tract Infections (URTI) at&#xD;
      High-Risk of Progression to Lower Respiratory Tract Infections (LRTI)&#xD;
&#xD;
      Part B - Recommended Phase 2 Dose (RP2D) cohort expansion in patients with URTIs at high-risk&#xD;
      of progression to LRTIs&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in viral load</measure>
    <time_frame>Day 28</time_frame>
    <description>Time to reduction in viral load in nasal swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in viral load measured by proportion of patients with &gt;50% reduction in viral load in nasal swab</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in clinical signs and symptoms measured by patient and Investigator reported assessment of respiratory clinical symptoms</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of ascending doses of ALVR106 (Part A) assessed through Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI)</measure>
    <time_frame>Day 365</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in viral load</measure>
    <time_frame>Day 60, Day 90, and Month 6</time_frame>
    <description>Reduction in viral load in nasal swab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression form URTI to LRTI</measure>
    <time_frame>Day 10, Day 28</time_frame>
    <description>Proportion of patients with progression to LRTI by Day 10 and Day 28</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Respiratory Tract Infections</condition>
  <condition>RSV Infection</condition>
  <condition>Human Metapneumovirus Infection</condition>
  <condition>Influenza</condition>
  <condition>Para Influenza</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, visually identical to ALVR106</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALVR106</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALVR106, visually identical to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALVR106</intervention_name>
    <description>Infusion, visually identical to placebo</description>
    <arm_group_label>ALVR106</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion, visually identical to ALVR106</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergone allogeneic, autologous, or cord blood stem cell transplantation at least 21&#xD;
             days prior to randomization and demonstrated engraftment with an absolute neutrophil&#xD;
             count &gt;500/µL&#xD;
&#xD;
          -  Detection of at least 1 target virus of interest (ie, RSV, influenza, hMPV, and/or&#xD;
             PIV)&#xD;
&#xD;
          -  Has an HLA type matching with at least 1 suitably matched ALVR106 cell line&#xD;
&#xD;
          -  Diagnosis of URTI, defined as all of the following:&#xD;
&#xD;
               -  New onset of at least 1 of the following respiratory symptoms for ≤4 days prior&#xD;
                  to screening: nasal congestion, runny nose, cough, or sore throat, or worsening&#xD;
                  of 1 of these chronic respiratory symptoms (associated with a previously existing&#xD;
                  diagnosis, eg, chronic rhinorrhea, seasonal allergies, or chronic lung disease).&#xD;
&#xD;
               -  Absence of significant hypoxia (ie, oxygen saturation ≥92% on room air) at&#xD;
                  screening and randomization, or need for exogenous oxygen.&#xD;
&#xD;
               -  Absence of abnormalities consistent with LRTI on a chest X-ray and/or CT scan as&#xD;
                  assessed by the local radiologist.&#xD;
&#xD;
          -  High-risk patients following HCT, who may have ANY of the following:&#xD;
&#xD;
               -  Lymphocyte count &lt;180/mm3&#xD;
&#xD;
               -  &lt;100 days following HCT&#xD;
&#xD;
               -  CD4 T cell count &lt;50/mm3 within 90 days following HCT&#xD;
&#xD;
               -  Ex vivo graft manipulation resulting in T cell depletion&#xD;
&#xD;
               -  Haploidentical transplantation&#xD;
&#xD;
               -  Undergone cord blood stem cell transplantation&#xD;
&#xD;
               -  Unrelated donor with at least one mismatch at one of the following four HLA-gene&#xD;
                  loci: HLA-A, -B, -C and -DRB1&#xD;
&#xD;
               -  Received T-cell depletion or alemtuzumab (Campath®)&#xD;
&#xD;
               -  Considered to be high risk for respiratory disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent&#xD;
             dose &gt;0.5 mg/kg/day)&#xD;
&#xD;
          -  Prior therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other&#xD;
             immunosuppressive T cell-targeted monoclonal antibodies&#xD;
&#xD;
          -  Proven or suspected infection by novel coronavirus disease 2019 (COVID-19) within 28&#xD;
             days&#xD;
&#xD;
          -  Evidence of Grade &gt;2 acute graft versus host disease (GVHD)&#xD;
&#xD;
          -  Known or presumed non-viral pneumonia or sinusitis secondary to any organism.&#xD;
&#xD;
          -  Receipt of another investigational antiviral treatment during the study or within 28&#xD;
             days prior to randomization or study treatment administration&#xD;
&#xD;
          -  Donor lymphocyte infusion or other T cell therapies performed &lt;21 days prior to&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amy Wheeler</last_name>
    <phone>833.409.2281</phone>
    <email>Clinicaltrials@allovir.com</email>
  </overall_contact>
  <reference>
    <citation>Vasileiou S, Turney AM, Kuvalekar M, Mukhi SS, Watanabe A, Lulla P, Ramos CA, Naik S, Vera JF, Tzannou I, Leen AM. Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2020 Jan;105(1):235-243. doi: 10.3324/haematol.2018.206896. Epub 2019 Apr 19.</citation>
    <PMID>31004020</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Paramyxoviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

